<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945424</url>
  </required_header>
  <id_info>
    <org_study_id>QIV08</org_study_id>
    <secondary_id>U1111-1143-8433</secondary_id>
    <nct_id>NCT01945424</nct_id>
  </id_info>
  <brief_title>Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry</brief_title>
  <official_title>Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a&#xD;
      prospectively recruited pregnancy surveillance program designed to collect and analyze&#xD;
      information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women will be enrolled in the registry prospectively (after exposure to QIV in&#xD;
      routine clinical settings but before knowledge of the pregnancy outcome). Women exposed to&#xD;
      QIV with or without adverse events will be recorded in the Global Pharmacovigilance Database&#xD;
      and medically reviewed. Pregnancy outcomes will be sought via questionnaires sent to the&#xD;
      reporter at enrollment, estimated time of delivery, and six months after delivery.&#xD;
      Descriptive statistical methods will be the primary approach for summarizing data.&#xD;
&#xD;
      No vaccine products will be provided or administered as part of this registry protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2013</start_date>
  <completion_date type="Actual">September 15, 2019</completion_date>
  <primary_completion_date type="Actual">September 15, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Months</target_duration>
  <primary_outcome>
    <measure>Number of cases and outcomes of pregnancies following exposure to QIV vaccine</measure>
    <time_frame>Up to six years</time_frame>
    <description>Data will be summarized using descriptive statistical methods and stratified by pregnancy outcome (spontaneous abortion, elective termination, fetal death/stillbirth, live birth) and timing of vaccine exposure. Infant outcomes include birth defects and physical and social development.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">244</enrollment>
  <condition>Pregnancy</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Pregnancy Cases</arm_group_label>
    <description>Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Influenza Vaccine (QIV)</intervention_name>
    <description>No Intervention as part of this protocol</description>
    <arm_group_label>Pregnancy Cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women will be enrolled in the registry prospectively (after exposure to&#xD;
             Quadrivalent Influenza Vaccine (QIV) but before the conduct of any prenatal tests that&#xD;
             could provide knowledge of the outcome of pregnancy). If the condition of the fetus&#xD;
             has already been assessed through prenatal testing (e.g., targeted ultrasound,&#xD;
             amniocentesis, etc.), such reports will be considered retrospective reports.&#xD;
             Retrospective reports are also eligible for the registry but they will be analyzed&#xD;
             separately from prospective reports.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  N/A&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofipasteurpregnancyregistry.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quadrivalent Influenza Vaccine</keyword>
  <keyword>Pregnancy Registry</keyword>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

